272130-84-4

Basic information

• Product Name: methyl 2-methyl-5-vinylbenzoate
• Synonyms: methyl 2-methyl-5-vinylbenzoate
• CAS NO: 272130-84-4
• Molecular Weight: 176.215
• Mol File: 272130-84-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 2-methyl-5-vinylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-methyl-5-vinylbenzoate(272130-84-4)
• EPA Substance Registry System: methyl 2-methyl-5-vinylbenzoate(272130-84-4)

Safety Data

• Hazardous Substances Data: 272130-84-4(Hazardous Substances Data)

Upstream product

• 675148-96-6 methyl 5-formyl-2-methylbenzoate 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 79669-50-4 methyl 2-methyl-5-bromobenzoate 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 58586-55-3 3-iodo-4-methylbenzaldehyde 

Downstream Products

• 675148-96-6 methyl 5-formyl-2-methylbenzoate 
• 1408294-48-3 methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-2,6-anhydro-3,5-dideoxy-3-C-[3′-(3-methylcarboxy-4-methyl)phenyl-prop-2′-enyl]-D-glycero-D-galacto-non-2-enonate 

Relevant articles and documents

Nitroxide derivative of ROCK kinase inhibitor

The invention provides a small molecular compound of a NO donor. The small molecular compound is characterized in that the small molecular compound is a compound shown represented by structural formula I shown in the description, or a stereoisomer, a geometrical isomer, a tautomer, a racemate, a deuterated isotope derivative, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof; and in the formula I, ring A is a substituted or unsubstituted heteroaromatic ring, X is selected from (CH2)n, n is selected from 0, 1, 2 and 3, R is a substituent group of terminal -O-NO2, R is selected from hydrogen, a hydroxyl group, halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group and a substituted or unsubstituted heteroalkyl group, and R and R are respectively and independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted naphthenic base or an amino protecting group, or R and R are connected to form a substituted or unsubstituted cyclic heteroalkyl group. The compound has a high-activity inhibition effect on ROCK kinase.

AMP deaminase inhibitors. 3. SAR of 3-(carboxyarylalkyl)coformycin aglycon analogues

N3-Substituted coformycin aglycon analogues with improved AMP deaminase (AMPDA) inhibitory potency are described. Replacement of the 5-carboxypentyl substituent in the lead AMPDA inhibitor 3-(5-carboxypentyl)-3,6,7,8- tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (2) described in the previous article with various carboxyarylalkyl groups resulted in compounds with 10- 100-fold improved AMPDA inhibitory potencies. The optimal N3 substituent had m-carboxyphenyl with a two-carbon alkyl tether. For example, 3-[2-(3-carboxy- 5-ethylphenyl)ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (43g) inhibited human AMPDA with a K(i) = 0.06 μM. The compounds within the series also exhibited > 1000-fold specificity for AMPDA relative to adenosine deaminase.